Oral probiotics and topical hydrocortisone may reduce severity of Psoriasis

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-11-27T20:00:14+05:30 | Updated On 27 Nov 2022 8:00 PM IST

Psoriasis area severity index (PASI), Dermatology life quality index (DLQI), and visual analogue scale (VAS) was improved in psoriasis patients who received oral probiotics with topical hydrocortisone. The findings of the study were published in the Journal of Dermatology Research and Practice.

There has been a recent increase with regard to the oral administration of probiotics for the treatment of psoriasis. Oral probiotics have been known (previous research) to have a positive role in the treatment of psoriasis. Since the anti-inflammatory effect of the branded preprobiotics, Lactocare® on the severity of ulcerative colitis and also on the serum electrolytes and trace elements in psoriasis has previously been published, this study by Ali Akbarzadeh and peers aimed to evaluate the effect of oral probiotic on the treatment of psoriasis.

A total of 52 patients with psoriasis were randomly divided into treatment and placebo (control) groups. The control group received topical hydrocortisone along with placebo, whereas in the treatment group, Lactocare® was orally administrated along with hydrocortisone.

The findings of this study were:

The mean value of VAS, DLQI, and PSAI were recorded and evaluated as pretreatment and post-treatment in both groups for a period of 3 months.
The mean of the values in the control groups were compared to the values in the treatment group.
Intragroup analysis was done comparing the mean of the scores at baseline 4-weeks, 8-weeks, and 12-weeks post-treatment .
A significant reduction was noticed in the PASI, VAS, and DLQI scores 12 weeks post-treatment in the treatment group when compared to the control group.

Source:

Akbarzadeh, A., Alirezaei, P., Doosti-Irani, A., Mehrpooya, M., & Nouri, F. (2022). The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. In C. G. Burkhart (Ed.), Dermatology Research and Practice (Vol. 2022, pp. 1–7). Hindawi Limited. https://doi.org/10.1155/2022/4549134

Source : Hindawi

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751